We are an incubator and accelerator driving innovative ideas in clinical diagnostics from discovery to proof-of-concept. Our proprietary approaches are commercialized through either licensing to industry leaders or the formation of focused spin-off ventures with dedicated research and business development teams.
Current focus
finding new biomarkers and confirming their clinical and laboratory relevance
using nano and micro-structured surfaces in biomedicine and pushing the boundaries of what is possible
In the background, we are building new products that can be distributed in the market due to their unique properties.
Latest news
GeneSpector today announced a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”), a world leader in supplying life sciences solutions and services. More
26/08/2024
Project pipelines
Product / technology (target/biomarker) | Discovery stage | Development | Scale-up | Commercialization | Commercial partner | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Proof-of-concept | Pre-clinic data | Clinical validation | CE / IVDR | Market | ||||||||||||
Sample Collection | Siemens , Viamar | |||||||||||||||
DNA/RNA Extraction Kit (CE IVD) | Immunotech, Siemens | |||||||||||||||
PCR COVID Kits (CE IVD) | Generi Biotech, Siemens | |||||||||||||||
Pregnancy-Related Complications Diagnostics (RT-PCR / miRNA Biomarker) | ||||||||||||||||
Multiple Myeloma Diagnostics (NGS/Set of Biomarkers) | ||||||||||||||||
Severity Predictor (RT-PCR / mRNA Biomarker) | ||||||||||||||||
Kidney Diagnostics (ELISA/MUC1 Biomarker) | Immunotech | |||||||||||||||
MALDI Plates | IQS Group, Affipro | |||||||||||||||
Lab-on-Card Technology | IQS Group |
Project galleryProof-of-conceptClinical validationCE / IVDRMarket
Sample Collection
We offer two innovative collection tubes. First of which we have developed a unique DNA/RNA transport and storage medium that immediately inactivates the viruses ensuring safety of your laboratory personnel. viRNAtrap™ Collection Tubes preserve the genetic integrity of samples at ambient temperature for weeks. Second of which is RESALIVA™ utilises an absorption sponge to collect saliva samples which is easy-to-use, pain-free, and comfortable.
viRNAtrap™ CE-IVDR Extraction Kit
Our fast and robust nucleic acid extraction is based on magnetic beads technology. viRNAtrap™ CE-IVDR Extraction Kit can be used for manual and automated nucleic acid purification on any open platform. The kit consists of 4 bottles not requiring controlled temperature storage. The isolation process takes 10 minutes only and enables true high-throughput extraction. The kit is CE-IVDR certified.
PCR solution for COVID-19 and other respiratory diseases
We have developed a high-quality PCR kit for rapid COVID-19 detection. The protocol is designed for about 60 minutes run time that allows laboratories to deliver the results much faster to patients and doctors. Our break-trough triplex PCR kit of COVID-INFA-INFB will provide fast confirmation of the infection type. All kits are CE IVD certified.
Pregnancy-Related Complications Diagnostics
GeneSpector offers a groundbreaking method for predicting pregnancy-related complications by analyzing blood samples during the first trimester (10th-13th week). This approach effectively predicts conditions like preeclampsia, fetal growth restriction, preterm birth, and gestational hypertension, significantly improving early intervention and prenatal care. It also identifies undiagnosed chronic hypertension, a key risk factor for complications, offering a high success rate in managing and preventing severe maternal and fetal outcomes.
Human NGS Diagnostics
A next-generation nucleic acid sequencing solution for various diagnostic applications feasible in any laboratory. Currently developing a kit for diagnosing multiple myeloma, a malignant bone marrow disorder, this innovative approach uses a custom set of oligonucleotides in a well-defined NGS panel followed by bioinformatics analysis to determine the disease cause directly. We also offer custom development of sequencing kits for other genetic-based disorder diagnostics and research.
Severity Predictor of Respiratory Infections
A diagnostic method predicting the severity of infectious disease symptoms days in advance. Using PCR-based detection of specific biomarkers in nasopharyngeal swabs, it identifies high-risk patients early, enabling timely therapy. Applicable to viral, bacterial, and fungal infections, it also monitors treatment efficacy. Optimized for large-scale testing. To develop the methodology and deliver a certified and proven test, GeneSpector decided to found a spin-off company called SeveriDx (www.severidx.com).
ELISA-based Diagnostics of Hereditary Kidney Diseases
A reliable, simple diagnostic solution for hereditary kidney disease ADTKD (Autosomal Dominant Tubulo-Interstitial Kidney Disease). Utilizing a specially developed ELISA-based method to detect the MUC1 protein in blood plasma, this cost-effective technique allows for comprehensive screening and monitoring of disease progression and therapy efficiency. Optimized for large-scale testing, this method provides an accessible alternative to expensive genetic testing and aims to be certified and marketed under a license-based collboration for a global use.
MALDI Plates for Mass Spectrometry
In collaboration with the company Affipro, we have initiated the development of a 3-D printed single-use device called sample target plate. They are currently used for the method called Microbe MALDI Biotyping, which is applied in clinical microbiology for the identification of pathogens without the need for time-consuming microbial growth in expensive selective media. Using nanotechnologies developed at IQS nano, we have already prepared new prototypes of these target plates, which exhibit good performance for MALDI Biotyping. They may represent a cost-effective and versatile alternative compared to the currently available equipment produced by traditional technologies.
Lab-on-Card Technology
Imagine a world where clinical diagnostics is done with nothing but a simple card. GeneSpector offers a groundbreaking solution using passive chips with nanofluidic structures for complex sample work-up, analyte detection, and result visualization. This method, executable anywhere—even in field conditions—provides robust, fast results with a simple readout at a low price. Applicable for diagnosing conditions like myocardial infarction and infectious diseases, it requires only a drop of a biological sample (e.g., blood, saliva, urine). To develop the technology, GeneSpector in collaboration with IQS Group decided to found a spin-off company in 2024 called Lab On Card (www.laboncard.com).
Our team
Our business and scientific teams work hand-in-hand to drive innovative diagnostic solutions from concept to reality. We're proud to accelerate ideas that can truly impact patient care.
Michal Pohludka, CEO & Co-founder
What's new
GeneSpector Announces Collaborative Agreement with Thermo Fisher Scientific EMEA Ltd. 25/08/24
GeneSpector today announced a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”), a world leader in supplying life sciences solutions and services.
Putting rapid clinical results into the hands of patients 18/01/23
The timely and accurate diagnosis of disease is necessary for treatments that maximize the patients’ survival and quality of life. For this, an ever-growing number of disease-related biomarkers is monitored, usually with expensive instruments. These tests may not be accessible at routine doctor’s appointments or even in emergency situations, as samples need to be sent for testing to large centralized laboratories, adding cost and delays of several days or more and the need for repeated visits.
Major breakthrough in the fight against AIDS 18/01/23
Acquired immunodeficiency syndrome, better known under the abbreviation AIDS, represents a spectrum of medical conditions caused by an infection with the human immunodeficiency virus (HIV). HIV is primarily transmitted via unprotected sex and contaminated hypodermic needles and targets white blood cells causing a gradual shutdown of host’s immune system. Such immunocompromised person is susceptible to a wide variety of secondary infections—which would otherwise pose no danger for a healthy individual—leading to the development of AIDS and, eventually, death.
Saving lives months ahead: prediction of risk of pregnancy complications 18/01/23
Complications in pregnancy affect 5 to 10% of women and can not only threaten the life or health of the mother and her child, but also cause irreversible changes in their metabolism and cardiovascular and cerebrovascular systems. However, current methods can only predict them with very limited success, based on the mother’s medical history, i.e., diseases occurring in the family, ultrasound and biochemical examination. Undetected and unmanaged changes can then manifest themselves years later in the form of heart attack, stroke, intellectual disability, diabetes, or metabolic disorders, so early prediction is the key to their successful management or even prevention.
Contact
Do not hesitate
to contact us:
General queries,
investors & partners
US subsidiary
GeneSpector Innovations USA, Inc.
3500 South Dupont Highway
Dover DE 19901
EU subsidiary
GeneSpector s.r.o.
Petrska 1180/3
110 00 Prague, Czech Republic